<bill session="118" type="h" number="3884" updated="2025-05-27T14:15:36Z">
  <state datetime="2024-09-23T15:28:12-04:00">PASS_OVER:HOUSE</state>
  <status>
    <unknown datetime="2024-09-23T15:28:12-04:00"/>
  </status>
  <introduced datetime="2023-06-07"/>
  <titles>
    <title type="short" as="reported to house">Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023</title>
    <title type="short" as="introduced">Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023</title>
    <title type="short" as="passed house">Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023</title>
    <title type="short">Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023</title>
    <title type="display">Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023</title>
    <title type="official" as="introduced">To amend title XI of the Public Health Service Act to reauthorize the program providing for sickle cell disease and other heritable blood disorders research, surveillance, prevention, and treatment.</title>
  </titles>
  <sponsor bioguide_id="B001248"/>
  <cosponsors>
    <cosponsor bioguide_id="C001103" joined="2023-06-07"/>
    <cosponsor bioguide_id="D000096" joined="2023-06-07"/>
    <cosponsor bioguide_id="L000551" joined="2023-07-19"/>
  </cosponsors>
  <actions>
    <action datetime="2023-06-07">
      <text>Introduced in House</text>
    </action>
    <action datetime="2023-06-07" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2023-06-09">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
    <action datetime="2023-07-13">
      <text>Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 28 - 0.</text>
    </action>
    <action datetime="2023-07-13">
      <text>Subcommittee Consideration and Mark-up Session Held</text>
    </action>
    <action datetime="2023-07-19">
      <text>Committee Consideration and Mark-up Session Held.</text>
    </action>
    <action datetime="2023-07-19" state="REPORTED">
      <text>Ordered to be Reported (Amended) by the Yeas and Nays: 50 - 0.</text>
    </action>
    <action datetime="2023-08-25">
      <text>Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-166.</text>
    </action>
    <calendar datetime="2023-08-25" calendar="Union" number="132">
      <text>Placed on the Union Calendar, Calendar No. 132.</text>
    </calendar>
    <action datetime="2024-09-23T15:13:18-04:00">
      <text>Mr. Bucshon moved to suspend the rules and pass the bill, as amended.</text>
    </action>
    <action datetime="2024-09-23T15:13:33-04:00">
      <text>Considered under suspension of the rules.</text>
      <reference ref="CR H5578-5580" label="consideration"/>
    </action>
    <action datetime="2024-09-23T15:13:36-04:00">
      <text>DEBATE - The House proceeded with forty minutes of debate on H.R. 3884.</text>
    </action>
    <vote how="by voice vote" type="vote" datetime="2024-09-23T15:28:12-04:00" where="h" result="pass" state="PASS_OVER:HOUSE">
      <text>On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.</text>
      <reference ref="CR H5578" label="text"/>
    </vote>
    <action datetime="2024-09-23T15:28:17-04:00">
      <text>Motion to reconsider laid on the table Agreed to without objection.</text>
    </action>
    <action datetime="2024-09-24">
      <text>Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referred To"/>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Reported By, Markup By, Referred To"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Reporting, Markup, Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Blood and blood diseases"/>
    <term name="Health programs administration and funding"/>
    <term name="Health promotion and preventive care"/>
    <term name="Hereditary and development disorders"/>
    <term name="Medical research"/>
  </subjects>
  <amendments/>
  <summary date="2024-09-18T17:00:03Z" status="Reported to House">Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023

This bill reauthorizes through FY2028 the Sickle Cell Disease Treatment Demonstration Program, which supports efforts to improve treatment and prevention of sickle cell disease and complications from that disease. (Sickle cell disease is an inherited blood disorder that can lead to pain, anemia, infections, and stroke.)&#160;</summary>
  <committee-reports>
    <report>H. Rept. 118-166</report>
  </committee-reports>
</bill>
